XML 20 R9.htm IDEA: XBRL DOCUMENT v3.7.0.1
GOODWILL AND OTHER INTANGIBLE ASSETS
3 Months Ended
Mar. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS
GOODWILL AND OTHER INTANGIBLE ASSETS

Changes in the carrying amount of goodwill for the three-month period ended March 31, 2017 were as follows:
 
Specialty
Surgical
Solutions
 
Orthopedics and
Tissue Technologies
 
Total
 
(In thousands)
Goodwill at December 31, 2016
$
284,358

 
$
226,213

 
$
510,571

Derma Sciences acquisition

 
66,488

 
66,488

Foreign currency translation
513

 
657

 
1,170

Balance, March 31, 2017
$
284,871

 
$
293,358

 
$
578,229



The components of the Company’s identifiable intangible assets were as follows:
 
March 31, 2017
 
Weighted
Average
Life
 
Cost
 
Accumulated
Amortization
 
Net
 
(Dollars in thousands)
Completed technology
17 years
 
$
491,698

 
$
(101,953
)
 
$
389,745

Customer relationships
13 years
 
231,257

 
(80,002
)
 
151,255

Trademarks/brand names
28 years
 
104,191

 
(19,997
)
 
84,194

Supplier relationships
27 years
 
34,721

 
(14,021
)
 
20,700

All other (1)
5 years
 
11,147

 
(2,633
)
 
8,514

 
 
 
$
873,014

 
$
(218,606
)
 
$
654,408


 
December 31, 2016
 
Weighted
Average
Life
 
Cost
 
Accumulated
Amortization
 
Net
 
(Dollars in thousands)
Completed technology
17 years
 
$
479,964

 
$
(94,991
)
 
$
384,973

Customer relationships
12 years
 
152,335

 
(77,005
)
 
75,330

Trademarks/brand names
30 years
 
90,507

 
(19,158
)
 
71,349

Supplier relationships
27 years
 
34,721

 
(13,664
)
 
21,057

All other (1)
5 years
 
10,806

 
(2,340
)
 
8,466

 
 
 
$
768,333

 
$
(207,158
)
 
$
561,175

 
(1) 
At March 31, 2017 and December 31, 2016, all other included in-process research and development ("IPR&D") of $1.0 million in both periods, which was indefinite-lived.
Based on quarter-end exchange rates, annual amortization expense (including amounts reported in cost of product revenues, but excluding any possible future amortization associated with acquired in-process research and development) is expected to be approximately $48.1 million in 2017, $48.9 million in 2018, $48.8 million in 2019, $48.7 million in 2020, $47.7 million in 2021 and $44.2 million in 2022. Identifiable intangible assets are initially recorded at fair market value at the time of acquisition using an income or cost approach.